[1] Article Title: Molecular characterization of congenital myasthenic syndromes in Spain
	•	Line(s): Title section (first page)
	•	Section: Title
	•	Quote(s): “Molecular characterization of congenital myasthenic syndromes in Spain”

⸻

[2] Publication Year: 2017
	•	Line(s): First page
	•	Section: Citation
	•	Quote(s): “Neuromuscular Disorders, Volume 27, Issue 12, December 2017”

⸻

[3] Region: Europe
	•	Line(s): Throughout (e.g., Abstract, Methods)
	•	Section: Abstract, Introduction
	•	Quote(s): “…CMS patients from Spain.”

⸻

[4] Country: Spain
	•	Line(s): Throughout (e.g., Abstract, Introduction, Methods)
	•	Section: Abstract, Introduction
	•	Quote(s): “…CMS patients from Spain.”

⸻

[5] Coverage Area: National
	•	Line(s): Introduction
	•	Section: Introduction
	•	Quote(s): “…data on patient cohorts from different countries are useful…” and “…different CMS subtypes in a large Spanish population.”

⸻

[6] Study Design: Cross-sectional observational study
	•	Line(s): Methods
	•	Section: Patients and Methods
	•	Quote(s): “All patients with genetically confirmed CMS followed-up…”
(Cross-sectional design inferred based on single-point data collection on genetic and clinical findings without longitudinal follow-up.)

⸻

[7] Study Population: Genetically confirmed CMS patients in Spain
	•	Line(s): Abstract, Methods
	•	Section: Abstract, Patients and Methods
	•	Quote(s): “…molecular genetic and clinical findings of sixty-four genetically confirmed CMS patients from Spain.”

⸻

[8] Population Characteristics: Age range 0.5 to 80 years; 24 males, 40 females; from 47 unrelated families
	•	Line(s): Molecular genetic findings
	•	Section: Results
	•	Quote(s): “Sixty-four patients (24 males, 40 females)… The mean age at last follow-up was 27 years, ranging from 0.5 to 80 years.”

⸻

[9] Data Source Type: Clinical data and genetic testing
	•	Line(s): Methods
	•	Section: Patients and Methods
	•	Quote(s): “All patients with genetically confirmed CMS…”

⸻

[10] Data Source Details: Eleven Spanish centres with pediatric and adult neurology clinics
	•	Line(s): Patients and Methods
	•	Section: Methods
	•	Quote(s): “Eleven centres, including 4 of the 5 centres recognized as CSUR… participated.”

⸻

[11] Study Timeline Type: Retrospective
	•	Line(s): Inferred from Methods
	•	Section: Methods
	•	Quote(s): “All patients with genetically confirmed CMS followed-up…”
(Retrospective nature inferred as analysis was performed on already diagnosed and followed-up patients.)

⸻

[12] Number of Sites: Multiple
	•	Line(s): Methods
	•	Section: Patients and Methods
	•	Quote(s): “Eleven centres… participated.”

⸻

[13] Study Start Year: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[14] Study End Year: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[15] Main Ethnicity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[16] Ethnicity Details: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[17] Disease Studied: Congenital myasthenic syndromes (CMS)
	•	Line(s): Abstract
	•	Section: Abstract
	•	Quote(s): “Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders…”

⸻

[18] Diagnosis Method: Genetic testing
	•	Line(s): Abstract, Methods
	•	Section: Abstract, Methods
	•	Quote(s): “…sixty-four genetically confirmed CMS patients…”

⸻

[19] Diagnosis Criteria Details: Genetic confirmation based on mutations in known CMS genes
	•	Line(s): Abstract, Results
	•	Section: Abstract, Results
	•	Quote(s): “Thirty-six mutations in the CHRNE, RAPSN, COLQ, GFPT1, DOK7, CHRNG, GMPPB, CHAT, CHRNA1, and CHRNB1 genes were identified…”

⸻

[20] Disease Phase: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[21] Cohort Age Group: Mixed
	•	Line(s): Results
	•	Section: Molecular genetic findings
	•	Quote(s): “…ranging from 0.5 to 80 years.”

⸻

[22] Female % in Cohort: 62.5%
	•	Line(s): Results
	•	Section: Molecular genetic findings
	•	Quote(s): “Sixty-four patients (24 males, 40 females)…”

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR